D. Boral Capital Reiterates Buy Rating for OS Therapies (NYSE:OSTX)

Key Points

• Investment analysts at D. Boral Capital have reaffirmed their "buy" rating for OS Therapies (NYSE:OSTX) with a price objective of $20.00.
• The stock experienced a 5.8% increase, opening at $2.39 and demonstrating significant growth potential with a market cap of $75.63 million.
• Recent institutional investments include Bridgeway Capital Management and XTX Topco Ltd, indicating positive sentiment and confidence in the company's future prospects.

OS Therapies (NYSE:OSTX - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $20.00 price objective on the stock.

OS Therapies Stock Up 5.3%

Shares of NYSE:OSTX traded up $0.11 on Tuesday, reaching $2.20. The company had a trading volume of 389,796 shares, compared to its average volume of 735,060. OS Therapies has a twelve month low of $1.12 and a twelve month high of $7.00. The stock has a 50-day moving average price of $1.92 and a 200 day moving average price of $1.75. The stock has a market capitalization of $69.62 million and a P/E ratio of -2.78.

Hedge Funds Weigh In On OS Therapies

Several large investors have recently made changes to their positions in OSTX. Bridgeway Capital Management LLC acquired a new position in shares of OS Therapies during the 2nd quarter worth about $47,000. XTX Topco Ltd acquired a new position in OS Therapies in the 2nd quarter valued at approximately $63,000. Finally, CM Management LLC lifted its position in shares of OS Therapies by 172.6% during the 1st quarter. CM Management LLC now owns 300,000 shares of the company's stock worth $462,000 after buying an additional 189,956 shares during the period.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.